Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effectiveness and Cost-Effectiveness of a Digital Care Pathway and Asynchronous Communication for Patients With Hypertension (DEPTH)

3 de setembro de 2026 atualizado por: Wellbeing Services County of Pirkanmaa

Digital Care Pathway and Asynchronous Communication for Primary Care Patients With Uncontrolled Hypertension: a Cluster-Randomized Controlled Trial

The goal of this clinical trial is to learn if digital care pathway (DCP) and digital non-real-time messaging, in other words, asynchronous communication (AC) with nurse works to treat high blood pressure in adults in primary care. It will also learn if DCP and AC are good value for money. The main questions it aims to answer are:

  • Does DCP and AC lower systolic blood pressure?
  • Are DCP and AC good value for money in treating high blood pressure? Researchers will compare usual care plus DCP and usual care plus DCP with AC to usual care only to see if DCP and AC works to treat high blood pressure.

Participants will:

  • Get usual care or usual care plus DCP or usual care plus DCP with AC for 6 months
  • Visit the study nurse at the start of the trial and after 6 months for checkup and tests which include usual laboratory tests for high blood pressure
  • Answer online survey questions and measure their blood pressure at home for 4 days at the start of the trial and after 6 months

Visão geral do estudo

Descrição detalhada

The study will be conducted as a prospective, cluster-randomized controlled trial in six primary healthcare centres within the Wellbeing Services County of Pirkanmaa, Finland. Randomization will be performed at the healthcare centre level, with two centres allocated to each study arm. Because of the nature of the interventions, neither participants nor healthcare professionals can be blinded to treatment allocation.

Before the study begins, one induction session will be organised at all participating healthcare centres. This session will give healthcare professionals information about the study protocol and recommendations for hypertension management. In addition, professionals working at centres allocated to the intervention arms will receive training in the use of the digital care pathway and asynchronous communication.

One nurse from each participating centre will be appointed as a part-time study nurse. The study nurses will be responsible for participant recruitment, conducting baseline and follow-up visits, and promoting study awareness within their respective healthcare centres. During the study, participants will be monitored either by the study nurse or by other healthcare professional familiar with the participant. Hypertension management is optimised in accordance with the participant's home blood pressure readings.

Participants will be recruited for the study over a period of 6-12 months. Data will be collected at baseline and at the end of the 6 month follow-up. Data sources will include study nurse assessments during study visits, electronic health records and registers of the Wellbeing Services County of Pirkanmaa, the digital care pathway, and electronic questionnaires via the REDCap digital research platform.

Based on power calculations, assuming a statistical power of 80 percent and a two-sided significance level of 0.05, a minimum of 182 participants per study arm is required to detect a between-group difference of at least 5 mmHg in the change in systolic blood pressure during follow-up (SD of change in systolic blood pressure 17 mmHg). Considering cluster randomization and participant dropout during follow-up, the target sample size is 200 participants per study arm, resulting in a total sample size of 600 participants.

The results will be presented as means and standard deviations (SDs) for continuous variables, and frequencies and percentages for categorical variables. Between-group comparisons will be conducted using Student's t-test for normally distributed continuous variables, the Mann-Whitney U test for non-normally distributed continuous variables, and Pearson's chi-squared test or Fisher's exact test for categorical variables. The effects of the interventions on change in systolic blood pressure will be analysed using regression-based methods that account for the clustered study design, such as linear mixed-effects model. According to the intention-to-treat principle, all participants recruited to the study will be included in the primary analyses, regardless of whether they remained in the study for the entire follow-up period. A two-sided p-value of less than 0.05 will be considered statistically significant. All statistical analyses will be performed using IBM SPSS Statistics software.

The cost-effectiveness of the interventions will be assessed by calculating the incremental cost-effectiveness ratio (ICER), based on differences in both costs and effectiveness between the study arms. Costs will be assessed from the healthcare system perspective.

Tipo de estudo

Intervencional

Inscrição (Estimado)

600

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Pirkanmaa
      • Akaa, Pirkanmaa, Finlândia
        • Akaa health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor
      • Sastamala, Pirkanmaa, Finlândia
        • Sastamala health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor
      • Tampere, Pirkanmaa, Finlândia
        • Hatanpää health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor
      • Tampere, Pirkanmaa, Finlândia
        • Hervanta health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor
      • Tampere, Pirkanmaa, Finlândia
        • Linnainmaa health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor
      • Valkeakoski, Pirkanmaa, Finlândia
        • Valkeakoski health and social services centre, The Wellbeing Services County of Pirkanmaa
        • Contato:
        • Investigador principal:
          • Tuomas Koskela, Professor

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • a diagnosis of hypertension for at least 3 months
  • an office blood pressure of ≥140/90 mmHg at baseline
  • access to a smartphone and the ability to use strong electronic identification for application login
  • ability to measure home blood pressure
  • ability to take care of the personal medication

Exclusion Criteria:

  • unwillingness to participate in the study
  • secondary hypertension or hypertensive crisis (office blood pressure >200/130 mmHg)
  • atrial fibrillation
  • stage 4 or 5 chronic kidney disease (eGFR <30 mL/min/1.73 m²)
  • a life expectancy of less than 1 year
  • pregnancy or breastfeeding
  • a clearly impaired ability to use the study interventions or participate in the study, as determined by a healthcare professional (e.g., insufficient Finnish language proficiency, dementia, psychiatric illness, or sensory impairments)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control
Usual Care for hypertension
Experimental: Digital Care Pathway
Usual Care + Digital Care Pathway for 6 months
Digital care pathway for hypertension is a web-based and mobile application that includes goal setting and education material for hypertension, entering home blood pressure values, medication list and medication intake, blood pressure self-test and self-care survey, reminders on measuring values, upcoming appointments and self-care guidance, motivational messages and diary.
Experimental: Digital Care Pathway and Asynchronous Communication
Usual Care + Digital Care Pathway with Asynchronous Communication with nurse for 6 months
Digital care pathway for hypertension is a web-based and mobile application that includes goal setting and education material for hypertension, entering home blood pressure values, medication list and medication intake, blood pressure self-test and self-care survey, reminders on measuring values, upcoming appointments and self-care guidance, motivational messages and diary.
Asynchronous communication means digital bidirectional non-real-time messaging between participant and nurse. It can be used with digital care pathway.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in the Office Systolic Blood Pressure Level at 6 Months
Prazo: Baseline and 6 months
Office systolic blood pressure is measured using a validated and calibrated blood pressure monitor in accordance with the 2024 European Society of Cardiology (ESC) guidelines. Three blood pressure measurements are taken by the study nurse during the office visit, and the average of the last two measurements is used as the participant's blood pressure level. If the blood pressure readings differ by more than 10 mmHg, additional measurements are taken.
Baseline and 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in the Home Systolic Blood Pressure Level at 6 Months
Prazo: Baseline and 6 months
Home systolic blood pressure is measured using a validated blood pressure monitor listed in the STRIDE BP database, in accordance with the Finnish Current Care Guidelines for Hypertension. Participants measure their seated cuff blood pressure twice in the morning and twice in the evening for four consecutive days. The home blood pressure level is defined as the mean of all recorded measurements.
Baseline and 6 months
Proportion of Participants with Controlled Blood Pressure at 6 months
Prazo: 6 months
Controlled blood pressure is defined as an office blood pressure level <140/90 mmHg and a home blood pressure level <135/85 mmHg according to the Finnish Current Care Guidelines for Hypertension
6 months
Change from Baseline in the Cardiovascular Disease Risk at 6 Months assessed by FINRISKI risk calculator
Prazo: Baseline and 6 months
The FINRISKI calculator is based on data on risk factors and morbidity follow-up from participants in the FINRISKI study conducted in 1982, 1987, 1992, 2002 and 2007. Data on morbidity and mortality among study participants over the 10-year follow-up period were obtained from Finnish registers. The FINRISKI calculator provides a percentage score that indicates participant's risk of suffering a heart attack or a stroke over the next 10 years. The percentage ranges from 0 to 100 percent, and a higher value indicates a worse outcome.
Baseline and 6 months
Change from Baseline in the Cardiovascular Disease Risk at 6 Months assessed by Systematic Coronary Risk Evaluation 2 (SCORE2) risk calculator
Prazo: Baseline and 6 months
The SCORE2 risk calculator provides an estimate of 10-year fatal and non-fatal cardiovascular disease risk for participants without previous CVD or diabetes aged 40-69 years in Europe. It gives a percentage score that ranges from 0 to 100 percent, and a higher value indicates a worse outcome.
Baseline and 6 months
Change from Baseline in Quality of Life at 6 Months
Prazo: Baseline and 6 months
Health related quality of life is measured with the EuroQoL-5D-5L questionnaire. The EQ-5D-5L questionnaire consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1 no problems, 2 slight problems, 3 moderate problems, 4 severe problems and 5 extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate level in each of the five dimensions. A higher level on each dimension indicates poorer health. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where participant rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Baseline and 6 months
Change from Baseline in Self-Care Preparedness Index at 6 Months
Prazo: Baseline and 6 months
The Self-Care Preparedness Index is assessed by a questionnaire for participants. The questionnaire contains six questions about participant's self-care. The index ranges from -5 to +5. A higher number indicates a higher level of self-care preparedness.
Baseline and 6 months
Change from Baseline in Medication Adherence at 6 Months
Prazo: Baseline and 6 months
Medication adherence is assessed by reviewing antihypertensive medication prescriptions issued and dispensed during the preceding 6 months. Prescription data will be obtained from the electronic health record system with the participant's consent. More prescriptions dispensed as instructed by a doctor means better outcome. The value can range from 0 percent of prescriptions dispensed to 100 percent prescriptions dispensed as instructed.
Baseline and 6 months
Participants' Perceptions of the Feasibility and Usability of DCP and AC assessed by a 5-point Likert Scale Questionnaire
Prazo: 6 months
The questionnaire is developed based on the Unified Theory of Acceptance and Use of Technology 2 (UTAUT2) model. The scale ranges from 1 (Totally disagree) to 5 (Totally agree).
6 months
Change from Baseline in Participant-Perceived Barriers to Hypertension Management at 6 Months
Prazo: Baseline and 6 months
Participant-perceived barriers to hypertension management are assessed using a 5-point Likert scale questionnaire based on the model by Khatib et al (2014). The scale ranges from 1 (Totally disagree) to 5 (Totally agree).
Baseline and 6 months
Number of Hypertension-Related Healthcare Contacts During Follow-Up
Prazo: From baseline to 6 months
The number of participant's healthcare contacts related to hypertension will be assessed after a 6-month follow-up using registry data of the Wellbeing Services County of Pirkanmaa. Healthcare contacts include all contacts (face-to-face and remote) with nurses and doctors at primary health care centers, as well as outpatient visits and inpatient hospital days in specialized healthcare.
From baseline to 6 months
Hypertension-Related Costs During Follow-Up
Prazo: From baseline to 6 months
The costs will be assessed after a 6-month follow-up by multiplying participant's hypertension-related healthcare contacts with their unit costs obtained from the official price list of the Wellbeing Services County of Pirkanmaa. All costs will be reported in euros (€).
From baseline to 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Tuomas Koskela, Professor, Chief Physician, Faculty of Medicine and Health Technology, Tampere University, Finland. The Wellbeing Services County of Pirkanmaa, Finland

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

28 de setembro de 2026

Conclusão Primária (Estimado)

1 de fevereiro de 2028

Conclusão do estudo (Estimado)

1 de agosto de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

25 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de setembro de 2026

Primeira postagem (Real)

10 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • R25071

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual participant data that underlie the results reported, after deidentification (text, tables, figures, and appendices).

Prazo de Compartilhamento de IPD

Beginning 3 months and ending 5 years after the publication of results.

Critérios de acesso de compartilhamento IPD

Upon reasonable request for researchers in the EU region.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever